61(top 2%)
papers
1.8K(top 1%)
citations
21(top 1%)
h-index
43(top 1%)
g-index
64
all documents
2.1K
doc citations
702
citing journals

Top Articles

#TitleJournalYearCitations
1NASH limits anti-tumour surveillance in immunotherapy-treated HCCNature2021649
2NAFLD and cardiovascular diseases: a clinical reviewClinical Research in Cardiology2021285
3Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY scoreJournal of Hepatology2022132
4Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)Gut2013105
5Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver DiseaseGastroenterology2020103
6The fecal mycobiome in non-alcoholic fatty liver diseaseJournal of Hepatology202266
7PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer—a randomised biomarker-driven clinical phase II AIO studyEuropean Journal of Cancer201855
8Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitisJournal of Hepatology202151
9Impact of Inhibitors of the Renin-Angiotensin-Aldosterone System on Liver Fibrosis and Portal HypertensionCurrent Medicinal Chemistry200642
10New cell surface markers for murine fetal hepatic stem cells identified through high density complementary DNA microarraysHepatology200741
11Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial.Journal of Clinical Oncology202239
12Botox, dilation, or myotomy? Clinical outcome of interventional and surgical therapies for achalasiaLangenbeck's Archives of Surgery201038
13CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks—A prospective randomized phase III study.Journal of Clinical Oncology201535
14Yersinia pseudotuberculosis bloodstream infection and septic arthritis: case report and review of the literatureInfection201234
15Cytolysin‐positive Enterococcus faecalis is not increased in patients with non‐alcoholic steatohepatitisLiver International202029
16Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’Anti-Cancer Drugs201028
17High Protein Intake Is Associated With Histological Disease Activity in Patients With NAFLDHepatology Communications202028
18Hepatosplenic candidiasisClinical Liver Disease201527
19Phenotyping non‐alcoholic fatty liver disease by the gut microbiota: Ready for prime time?Journal of Gastroenterology and Hepatology (Australia)202027
20Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life CohortLiver Cancer202125
21Acoustic Structure Quantification Ultrasound Software Proves Imprecise in Assessing Liver Fibrosis or Cirrhosis in Parenchymal Liver DiseasesUltrasound in Medicine and Biology201423
22Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the ‘burden of therapy’ methodEuropean Journal of Cancer202121
23Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive toolsScientific Reports202020
24Maternal exercise conveys protection against NAFLD in the offspring via hepatic metabolic programmingScientific Reports202018
25Neighbor of punc E11, a novel oncofetal marker for hepatocellular carcinomaInternational Journal of Cancer201115
26CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer – Final resultsEuropean Journal of Cancer202015
27Structured Reporting of Solid and Cystic Pancreatic Lesions in CT and MRI: Consensus-Based Structured Report Templates of the German Society of Radiology (DRG)RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren202015
28Neighbor of Punc E 11: Expression Pattern of the New Hepatic Stem/Progenitor Cell Marker During Murine Liver DevelopmentStem Cells and Development201214
29Hepatocyte expression of angiotensin II type 1 receptor is downregulated in advanced human liver fibrosisLiver International200911
30Inhibition of hepatitis C virus gene expression by adenoviral vectors encoding antisense RNA in vitro and in vivoJournal of Hepatology201111
31Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug targetMolecular and Clinical Oncology201711
32Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy‐proven non‐alcoholic fatty liver diseaseLiver International202111
33Fatal disseminated enterovirus infection in a patient with follicular lymphoma undergoing obinutuzumab maintenance therapyEuropean Journal of Haematology20198
34Panitumumab in combination with gemcitabine/cisplatin (GemCis) for patients with advanced kRAS WT biliary tract cancer: A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Journal of Clinical Oncology20158
35Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Updated final results of the randomized phase II AIO-NEONAX trial.Journal of Clinical Oncology20228
36HBsAg-negative/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation?Infection20196
37Hepatocellular carcinoma surveillance with liver imaging is not associated with improved survivalScandinavian Journal of Gastroenterology20206
38Any alcohol use in NAFLD patients is associated with significant changes to the intestinal viromeHepatology20236
39Randomized dose comparison phase II study of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) in patients with advanced hepatocellular carcinoma (HCC).Journal of Clinical Oncology20135
40Contrast-Enhanced Ultrasound for the Detection of Abdominal Complications in Infective Endocarditis: First Experience From a Prospective CohortUltrasound in Medicine and Biology20204
41Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib – results from a non-interventional multi-center studyBMC Cancer20203
42First evaluation of Neighbor of Punc E11 (NOPE) as a novel marker in human hepatocellular carcinomaCancer Biomarkers20213
43C-MET mRNA expression in pancreatic ductal adenocarcinoma and stromal tissue: Prognostic and therapeutic implications.Journal of Clinical Oncology20143
44ACCEPT: Afatinib as cancer therapy for exocrine pancreatic tumors–An explorative randomized phase II trial.Journal of Clinical Oncology20152
45Dietary omega-6/omega-3 ratio is not associated with gut microbiota composition and disease severity in patients with nonalcoholic fatty liver diseaseNutrition Research20222
46A peculiar case of autoimmune pancreatitis and sclerosing cholangitisEndoscopy20121
47Gemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: An explorative randomized AIO phase II trial (ACCEPT)Annals of Oncology20181
48Successful use of TNFα blockade in a severe case of idiopathic non-granulomatous ulcerative jejunoileitis associated with thrombotic thrombocytopenic purpuraBMJ Open Gastroenterology20191
49Palliation of malignant dysphagia with a segmented self-expanding metal stentMedicine (United States)20211
50Correlation of hand-foot skin reaction (HFS) with treatment efficacy in pancreatic cancer (PC) patients (pts) treated with gemcitabine/capecitabine plus erlotinib: A subgroup analysis from the AIO-PK0104 randomized, cross-over phase III trial in advanced PC.Journal of Clinical Oncology20121